Seeking Alpha

Myriad Genetics (MYGN) says that a study published in the British Journal of Cancer has...

Myriad Genetics (MYGN) says that a study published in the British Journal of Cancer has demonstrated, with highly statistically significant results, the ability of it's Homologous Recombination Deficiency Assay to detect loss of DNA repair in ovarian tumors.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|